세계의 셀 기반 어세이 시장 : 제공 제품별, 기술별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The cell-based assays market is projected to reach USD 27.55 billion by 2030 from an estimated USD 17.84 billion in 2025, at a CAGR of 9.1% during the forecast period from 2025 to 2030. This growth can be largely attributed to the increasing demand for drug discovery and the rising need for cell-based assays in this area. Furthermore, higher research & development investments from the pharmaceutical and biotechnology industries are driving the growth of the cell-based assays market. Additionally, the growing incidence of cancer is increasing the demand for advanced therapies, which further boosts market expansion. The expanding applications of cell-based assays in chronic diseases and personalized medicine are also expected to propel market growth in the coming years.

"The drug discovery segment accounted for the largest share of the application segment in 2024."

The cell-based assays market is segmented by application into drug discovery, basic research, genetic studies, and other applications. The drug discovery segment is further categorized into toxicity, pharmacokinetic, and pharmacodynamic studies. In 2024, the drug discovery segment accounted for the largest share of the global cell-based assays market. The increasing prevalence of cancer is driving the demand for advanced therapies, which, in turn, promotes the growth of this segment within the cell-based assays market. Additionally, rising investments in research and development, the introduction of new drugs, and a growing number of contract research organizations offering drug discovery services to pharmaceutical and biotechnology companies are also expected to contribute to the segment's continued growth in the cell-based assays market.

"The flow cytometry segment accounted for a major share of the technology market in 2024."

The cell-based assays market is categorized by technology into flow cytometry, high-throughput screening, label-free detection, and other technologies. In 2024, flow cytometry held the largest share of the global cell-based assays market within this category. The growth of the flow cytometry segment is primarily due to its widespread use in cell-based assays, allowing for multiple measurements. Additionally, the increasing adoption of advanced technologies for cell analysis and characterization is expected to further enhance the growth of this segment in the cell-based assays market.

"The US dominated the cell-based assays market in 2024."

The cell-based assays market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated the cell-based assays market in North America. As the largest biopharmaceutical market in the world, the US leads in biopharmaceutical research and investments. The country also boasts a robust healthcare infrastructure that supports research and development in the life sciences sector.

Additionally, the significant presence of numerous biopharmaceutical companies and increased research activities in the biotechnology industry are driving market growth in the US. Furthermore, the rising emphasis on developing advanced cell-based therapies, prompted by the increasing incidence of cancer, contributes to the growth of the cell-based assays market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side (60%) and Demand Side (40%)
• By Designation: Managers (45%), CXOs & Directors (30%0, and Executives (25%)
• By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Companies Profiled in the Report:

• BD (US)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• Merck KGaA (Germany)
• Agilent Technologies, Inc. (US)
• Lonza (Switzerland)
• Charles River Laboratories (US)
• Bio-Rad Laboratories, Inc. (US)
• REVVITY (US)
• Sartorius AG (Germany)
• Corning Incorporated (US)
• Promega Corporation (US)
• Cell Signaling Technology, Inc. (US)
• Eurofins Scientific (Luxembourg)
• Enzo Biochem, Inc. (US)
• Carna Biosciences, Inc. (Japan)
• Intertek Group Plc (UK)
• BICO (Sweden)
• Cell Biolabs, Inc. (US)
• Reaction Biology (US)
• AAT Bioquest, Inc. (US)
• Pestka Biomedical Laboratories, Inc. (US)
• Neuromics (US)
• BPS Bioscience, Inc. (US)
• BellBrook Labs (US)
• Profacgen (US)
• BMG LABTECH (Germany)
• Hanugen Therapeutics (India)
• Altogen Labs (US)
• BioAgilytix (US)

Research Coverage:

This research report categorizes the cell-based assays market by offering {consumables [reagents, assay kits (reporter gene assays, cell growth assays, secondary messenger assays, cell death assays, and other assay kits), microplates, cell lines (immortalized cell lines, primary cell lines, and stem cell lines), probes & labels, and other consumables], instruments, software, and services}, technology (flow cytometry, high-throughput screening, label-free detection, and other technologies), application [drug discovery (toxicology, pharmacodynamics, and pharmacokinetics), basic research, genetic studies, and other applications], end user (pharmaceutical & biopharmaceutical companies, contract research organizations (CROs), and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell-based assays market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This analysis also includes information about new product launches, collaborations, acquisitions, and recent developments related to the cell-based assays market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall cell-based assays market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising demand for drug discovery & development and increasing preference for cell-based assays in drug discovery, a surge in cases of cancer, and increasing R&D investments and funding for cell-based research), restraints (high cost of instruments and restrictions imposed by product end-user licenses for reagents), opportunities (growing applications of cell-based assays in chronic diseases and personalized medicine), and Challenges (complexities in assay designs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the cell-based assays market.
• Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell-based assays market.
• Competitive Assessment: BD (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Lonza (Switzerland), Charles River Laboratories (US), Bio-Rad Laboratories, Inc. (US), REVVITY (US), Sartorius AG (Germany), Corning Incorporated (US), Promega Corporation (US), Cell Signaling Technology, Inc. (US), Eurofins Scientific (Luxembourg), Enzo Biochem, Inc. (US), Carna Biosciences, Inc. (Japan), Intertek Group Plc (UK), BICO (Sweden), Cell Biolabs, Inc. (US), Reaction Biology (US), AAT Bioquest, Inc. (US), Pestka Biomedical Laboratories, Inc. (US), Neuromics (US), BPS Bioscience, Inc. (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), Altogen Labs (US), and BioAgilytix (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 INCLUSIONS & EXCLUSIONS
  • 1.3.2 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH)
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL-BASED ASSAYS MARKET
• 4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2024)
• 4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2024
• 4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2024
• 4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery
    • 5.2.1.2 Government support and funding for cell-based research
    • 5.2.1.3 Growing efforts to curtail animal-based studies
    • 5.2.1.4 Rising prevalence of cancer
    • 5.2.1.5 Alliances to accelerate innovations in drug discovery
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of instruments and restrictions imposed by product end-user licenses for reagents
    • 5.2.2.2 Lack of standardization of protocols used in cell-based assays
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine
    • 5.2.3.2 Growth opportunities in emerging economies
    • 5.2.3.3 Rising adoption of AI in drug discovery and cell analysis
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complexities in assay designs
    • 5.2.4.2 Shortage of skilled professionals
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Flow cytometry
    • 5.3.1.2 High-throughput screening
    • 5.3.1.3 High-content screening
    • 5.3.1.4 Label-free detection
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Artificial intelligence and machine learning
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 Nanotechnology
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021-2024
  • 5.5.2 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 RAW MATERIAL VENDORS
  • 5.6.2 PRODUCT/SERVICE VENDORS
  • 5.6.3 END USERS
  • 5.6.4 REGULATORY BODIES
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.8 PATENT ANALYSIS
  • 5.8.1 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2014-2025
• 5.9 KEY CONFERENCES & EVENTS, 2025-2026
• 5.10 TARIFF AND REGULATORY LANDSCAPE
  • 5.10.1 TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.3 REGULATORY FRAMEWORK
    • 5.10.3.1 North America
    • 5.10.3.2 Europe
    • 5.10.3.3 Asia Pacific
    • 5.10.3.4 Rest of the World
• 5.11 PORTER'S FIVE FORCES ANALYSIS
  • 5.11.1 THREAT OF NEW ENTRANTS
  • 5.11.2 THREAT OF SUBSTITUTES
  • 5.11.3 BARGAINING POWER OF SUPPLIERS
  • 5.11.4 BARGAINING POWER OF BUYERS
  • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 INVESTMENT AND FUNDING SCENARIO
• 5.14 TRADE ANALYSIS
  • 5.14.1 IMPORT DATA
  • 5.14.2 EXPORT DATA
• 5.15 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET
• 5.16 IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 KEY TARIFF RATES
  • 5.16.3 PRICE IMPACT ANALYSIS
  • 5.16.4 IMPACT ON COUNTRY/REGION
    • 5.16.4.1 US
    • 5.16.4.2 Europe
    • 5.16.4.3 Asia Pacific
  • 5.16.5 IMPACT ON END-USE INDUSTRIES
    • 5.16.5.1 Pharmaceutical & biotech companies
    • 5.16.5.2 Contract research organizations (CROs)
    • 5.16.5.3 Academic & research institutes

6 CELL-BASED ASSAYS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 CONSUMABLES
  • 6.2.1 REAGENTS
    • 6.2.1.1 High demand for reagents in research applications to propel market growth
  • 6.2.2 ASSAY KITS
    • 6.2.2.1 Reporter gene assays
      • 6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth
    • 6.2.2.2 Cell growth assays
      • 6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market
    • 6.2.2.3 Secondary messenger assays
      • 6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth
    • 6.2.2.4 Cell death assays
      • 6.2.2.4.1 Importance of cell death quantification in drug development to favor growth
    • 6.2.2.5 Other assay kits
  • 6.2.3 MICROPLATES
    • 6.2.3.1 Demand for microplates in assay development to drive market
  • 6.2.4 CELL LINES
    • 6.2.4.1 Immortalized cell lines
      • 6.2.4.1.1 Wide use of immortalized cell lines to boost market
    • 6.2.4.2 Primary cell lines
      • 6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market
    • 6.2.4.3 Stem cell lines
      • 6.2.4.3.1 Rising use in tissue and disease models to fuel adoption
  • 6.2.5 PROBES & LABELS
    • 6.2.5.1 Growing need for effective cell labeling to boost demand
  • 6.2.6 OTHER CONSUMABLES
• 6.3 INSTRUMENTS
  • 6.3.1 AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH
• 6.4 SERVICES
  • 6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH
• 6.5 SOFTWARE
  • 6.5.1 INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH

7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 FLOW CYTOMETRY
  • 7.2.1 WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET
• 7.3 HIGH-THROUGHPUT SCREENING
  • 7.3.1 INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
• 7.4 LABEL-FREE DETECTION
  • 7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND
• 7.5 OTHER TECHNOLOGIES

8 CELL-BASED ASSAYS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DRUG DISCOVERY
  • 8.2.1 TOXICITY STUDIES
    • 8.2.1.1 Increasing demand for cell-based assays in toxicity testing to fuel growth
  • 8.2.2 PHARMACOKINETIC STUDIES
    • 8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays
  • 8.2.3 PHARMACODYNAMIC STUDIES
    • 8.2.3.1 Advantages of cell-based assays in pharmacodynamics to propel growth
• 8.3 BASIC RESEARCH
  • 8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES
• 8.4 GENETIC STUDIES
  • 8.4.1 INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET
• 8.5 OTHER APPLICATIONS

9 CELL-BASED ASSAYS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET
• 9.3 CONTRACT RESEARCH ORGANIZATIONS
  • 9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET

10 CELL-BASED ASSAYS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 Established pharmaceutical and biotechnology sectors to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Increasing funding and investments to drive market
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK
  • 10.3.2 GERMANY
    • 10.3.2.1 To dominate cell-based assays market in Europe
  • 10.3.3 UK
    • 10.3.3.1 Growing cancer research funding to increase demand for cell-based assays
  • 10.3.4 FRANCE
    • 10.3.4.1 Growing biotechnology sector to drive market
  • 10.3.5 ITALY
    • 10.3.5.1 Growth of pharmaceutical industry to boost market
  • 10.3.6 SPAIN
    • 10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 MACROECONOMIC OUTLOOK
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing R&D expenditure to favor market growth
  • 10.4.3 JAPAN
    • 10.4.3.1 Government initiatives for drug innovation to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Increasing investments in R&D and funding for life science research to propel market
  • 10.4.5 AUSTRALIA
    • 10.4.5.1 Booming life science sector to propel market
  • 10.4.6 SOUTH KOREA
    • 10.4.6.1 Increasing strategic alliances to support market growth
  • 10.4.7 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 Brazil to hold largest share of Latin American market
  • 10.5.3 MEXICO
    • 10.5.3.1 Government support for biopharmaceutical production to support market growth
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST
  • 10.6.1 MACROECONOMIC OUTLOOK
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Saudi Arabia
      • 10.6.2.1.1 Increasing R&D investments to drive market
    • 10.6.2.2 UAE
      • 10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities
    • 10.6.2.3 Rest of GCC Countries
  • 10.6.3 REST OF MIDDLE EAST
• 10.7 AFRICA
  • 10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
  • 10.7.2 MACROECONOMIC OUTLOOK

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL-BASED ASSAYS MARKET
• 11.3 REVENUE ANALYSIS, 2020-2024
• 11.4 MARKET SHARE ANALYSIS, 2024
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Offering footprint
    • 11.5.5.3 Technology footprint
    • 11.5.5.4 Application Footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 11.6.5.1 Detailed list of key startups/SMEs
    • 11.6.5.2 Competitive benchmarking of key emerging players/startups
• 11.7 COMPANY VALUATION & FINANCIAL METRICS
• 11.8 BRAND/PRODUCT COMPARISON
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

• 12.1 INTRODUCTION
• 12.2 KEY PLAYERS
  • 12.2.1 DANAHER
    • 12.2.1.1 Business overview
    • 12.2.1.2 Products/Services offered
    • 12.2.1.3 Recent developments
      • 12.2.1.3.1 Deals
      • 12.2.1.3.2 Expansions
    • 12.2.1.4 MnM view
      • 12.2.1.4.1 Key strengths
      • 12.2.1.4.2 Strategic choices
      • 12.2.1.4.3 Weaknesses & competitive threats
  • 12.2.2 THERMO FISHER SCIENTIFIC INC.
    • 12.2.2.1 Business overview
    • 12.2.2.2 Products/Services offered
    • 12.2.2.3 Recent developments
      • 12.2.2.3.1 Deals
      • 12.2.2.3.2 Expansions
      • 12.2.2.3.3 Other developments
    • 12.2.2.4 MnM view
      • 12.2.2.4.1 Key strengths
      • 12.2.2.4.2 Strategic choices
      • 12.2.2.4.3 Weaknesses & competitive threats
  • 12.2.3 MERCK KGAA
    • 12.2.3.1 Business overview
    • 12.2.3.2 Products/Services offered
    • 12.2.3.3 Recent developments
      • 12.2.3.3.1 Deals
      • 12.2.3.3.2 Expansions
    • 12.2.3.4 MnM view
      • 12.2.3.4.1 Key strengths
      • 12.2.3.4.2 Strategic choices
      • 12.2.3.4.3 Weaknesses & competitive threats
  • 12.2.4 BD
    • 12.2.4.1 Business overview
    • 12.2.4.2 Products/Services offered
    • 12.2.4.3 Recent developments
      • 12.2.4.3.1 Product launches
      • 12.2.4.3.2 Deals
    • 12.2.4.4 MnM view
      • 12.2.4.4.1 Key strengths
      • 12.2.4.4.2 Strategic choices
      • 12.2.4.4.3 Weaknesses & competitive threats
  • 12.2.5 AGILENT TECHNOLOGIES, INC.
    • 12.2.5.1 Business overview
    • 12.2.5.2 Products/Services offered
    • 12.2.5.3 Recent developments
      • 12.2.5.3.1 Product launches
    • 12.2.5.4 MnM view
      • 12.2.5.4.1 Key strengths
      • 12.2.5.4.2 Strategic choices
      • 12.2.5.4.3 Weaknesses & competitive threats
  • 12.2.6 LONZA
    • 12.2.6.1 Business overview
    • 12.2.6.2 Products/Services offered
    • 12.2.6.3 Recent developments
      • 12.2.6.3.1 Deals
      • 12.2.6.3.2 Expansions
  • 12.2.7 EUROFINS SCIENTIFIC
    • 12.2.7.1 Business overview
    • 12.2.7.2 Products/Services offered
    • 12.2.7.3 Recent developments
      • 12.2.7.3.1 Deals
  • 12.2.8 CHARLES RIVER LABORATORIES
    • 12.2.8.1 Business overview
    • 12.2.8.2 Products/services offered
    • 12.2.8.3 Recent developments
      • 12.2.8.3.1 Service launches
      • 12.2.8.3.2 Deals
  • 12.2.9 BIO-RAD LABORATORIES, INC.
    • 12.2.9.1 Business overview
    • 12.2.9.2 Products/Services offered
  • 12.2.10 REVVITY
    • 12.2.10.1 Business overview
    • 12.2.10.2 Products/Services offered
    • 12.2.10.3 Recent developments
      • 12.2.10.3.1 Product launches
  • 12.2.11 SARTORIUS AG
    • 12.2.11.1 Business overview
    • 12.2.11.2 Products/Services offered
    • 12.2.11.3 Recent developments
      • 12.2.11.3.1 Expansions
  • 12.2.12 CORNING INCORPORATED
    • 12.2.12.1 Business overview
    • 12.2.12.2 Products/Services offered
  • 12.2.13 PROMEGA CORPORATION
    • 12.2.13.1 Business overview
    • 12.2.13.2 Products/Services offered
    • 12.2.13.3 Recent developments
      • 12.2.13.3.1 Product launches
  • 12.2.14 CELL SIGNALING TECHNOLOGY, INC.
    • 12.2.14.1 Business overview
    • 12.2.14.2 Products/Services offered
  • 12.2.15 ENZO BIOCHEM INC.
    • 12.2.15.1 Business overview
    • 12.2.15.2 Products/Services offered
    • 12.2.15.3 Recent developments
      • 12.2.15.3.1 Expansions
  • 12.2.16 CARNA BIOSCIENCES, INC.
    • 12.2.16.1 Business overview
    • 12.2.16.2 Products/Services offered
  • 12.2.17 INTERTEK GROUP PLC
    • 12.2.17.1 Business overview
    • 12.2.17.2 Products/services offered
    • 12.2.17.3 Recent developments
      • 12.2.17.3.1 Expansions
  • 12.2.18 BICO
    • 12.2.18.1 Business overview
    • 12.2.18.2 Products/Services offered
• 12.3 OTHER PLAYERS
  • 12.3.1 CELL BIOLABS, INC.
  • 12.3.2 REACTION BIOLOGY
  • 12.3.3 AAT BIOQUEST, INC.
  • 12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC.
  • 12.3.5 NEUROMICS
  • 12.3.6 BPS BIOSCIENCE, INC.
  • 12.3.7 BELLBROOK LABS
  • 12.3.8 PROFACGEN
  • 12.3.9 BMG LABTECH GMBH
  • 12.3.10 HANUGEN THERAPEUTICS
  • 12.3.11 ALTOGEN LABS
  • 12.3.12 BIOAGILYTIX LABS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS